Led by a team of industry experts, 3R Therapeutics is developing high-end and complex cannabinoids based pharmaceutical products to address chronic ocular diseases for patients around the world.
Our Research and Development unit based in Israel is licensed to conduct scientific and clinical research on cannabinoid formulations, by the Ministry of Health - IMC. As such, we are conducting in-depth research and developing cannabinoid-based medicines for patients suffering from complex chronic ophthalmic conditions.
We are committed to developing the next generation of ocular therapeutics with the help of cannabinoids. These patent-pending cannabinoid-based medicines provide a novel treatment option for various conditions that are currently insufficiently addressed.
Chronic ocular surface diseases affect between 15-20% of a global population. For most of these chronic ailments there are no long term treatments, no FDA approved protocols, while exiting antibiotics or steroids can not be used continuously without significant side effects.
Our mission is to unlock and exploit the potential of cannabinoid-based medicines, in order to address serious conditions, that currently have limited or no treatment options.
In order to provide an effective solution to ocular issues, 3R Therapeutics is developing a patented ocular cannabinoid treatment method using cannabinoid-based formulations.
We aim to provide efficient ocular treatment formulations and procedures for various intricate eye conditions.
MICHAEL RUBINOV (BSEE, MSCS, MBA)
Michael Rubinov is a business executive with broad experience in sales, marketing, business strategy, and international business development.
Business experience covers industries: Silicon, Telecom, VOIP, Cyber, Fintech, and various geographies: USA, Europe, Japan, Israel, and Latin America.
Michael holds BsEE from New York Institute of Technology, Master of Science (MsCS) from Stevens Institute of Technology, and MBA from Bradford (UK) School of Management.
Michael brings vast business knowledge coupled with entrepreneurial spirit and passion to succeed through learning and perseverance.
DR. IRENE ZEITOUN (PHD, MBA)
Chief Scientific Officer
Dr. Zeitoun is an exceptional leader with roots in science and vast experience in Pharma and Cannabis Industries in various managerial positions. She is a consultant, a mentor and a lecturer on various topics.
Worked for Hi-Pharma (Medical Cannabis Company), Targia Pharmaceuticals, Targetech (technological incubator), Manager of Industrial Research Services at Ramot (TAU), Ester Neurosciences, Mindset BioPharmaceuticals and consulting to various companies.
Dr. Zeitoun holds a Ph.D (Cum Laude) in Neurophysiology from the Faculty of Medicine of the Technion, a MSc. (Summa cum Laude) in Physiology & Pharmacology from TAU and a MBA from the Leon Recanati Business school (TAU).
PROFESSOR MICHAEL BELKIN (M.A, MD)
Prof. Belkin received an M.A. degree in Science from Cambridge University, England, and an M.D. degree in Medicine from the Hebrew University of Jerusalem, Israel. He is the author of over 250 scientific publications and holds over 25 patents.
Prof Belkin established and was the first full-time director of the Tel Aviv University Goldshlager Eye Research Institute. He was also:
Head of the pediatric ophthalmology services at Hadassah University Hospital and the Sheba Medical Center
Chairman of the Tel Aviv University Department of Ophthalmology
President of the Israel Society of Eye and Vision Research of which he was a co-founder
Chairman, Permanent Advisory Committee in Ophthalmology, Ministry of Health.
Incumbent of the Tel Aviv University Sidney A. Fox Chair of Ophthalmology
Chairman, Ophthalmology Committee, National Councils for Health
Chairman, Commercial Relationship Committee, Association for Research in Vision and Ophthalmology (ARVO)
Head of the Research and Development branch of the Israeli military medical department
DANA RUBIN (MBA)
Advisory Board, Regulation Expert
Dana is an alumni of California State University, Chapman University’s George L. Argyros School of Business and Economics, and is currently attending the University of Maryland, School of Pharmacy for a Master’s of Science in Medical Cannabis and Therapeutics.
Dana is a leading expert in pharmaceutical and cannabis biotechnology. Her company, PharmaConsult LTD advises companies on regulatory guidance, FDA compliance, and product formulation. Her past experience includes working with a generic pharmaceutical company that has a pipeline of FDA targeted products (totaling over 1B+ in brand sales) and licensing partnerships with leading multibillion-dollar pharmaceutical companies.
GET IN TOUCH